Compare PMTS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | MGNX |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 262.4M |
| IPO Year | 2015 | 2013 |
| Metric | PMTS | MGNX |
|---|---|---|
| Price | $25.95 | $2.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $32.50 | $8.00 |
| AVG Volume (30 Days) | 124.5K | ★ 904.5K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $312,189,000.00 | $149,500,000.00 |
| Revenue This Year | $11.19 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $77.24 | ★ N/A |
| Revenue Growth | ★ 12.27 | N/A |
| 52 Week Low | $10.81 | $1.29 |
| 52 Week High | $31.25 | $5.08 |
| Indicator | PMTS | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 31.85 |
| Support Level | $24.36 | $1.64 |
| Resistance Level | $26.23 | $3.46 |
| Average True Range (ATR) | 0.88 | 0.32 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 38.54 | 26.39 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.